{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:07:59Z","timestamp":1785838079996,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00198-022-06420-z","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T06:02:38Z","timestamp":1652680958000},"page":"1783-1794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reduced hip bone mineral density is associated with high levels of calciprotein particles in patients with Fabry disease"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-6711","authenticated-orcid":false,"given":"S.","family":"Bruell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-2423","authenticated-orcid":false,"given":"T. D.","family":"Hewitson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ruderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"6420_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","volume":"109","author":"PN De Francesco","year":"2013","unstructured":"De Francesco PN, Mucci JM, Ceci R, Fossati CA, Rozenfeld PA (2013) Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab 109:93\u201399. https:\/\/doi.org\/10.1016\/j.ymgme.2013.02.003","journal-title":"Mol Genet Metab"},{"key":"6420_CR2","doi-asserted-by":"publisher","first-page":"1221 e1221","DOI":"10.1016\/j.cjca.2015.10.033","volume":"32","author":"KH Chen","year":"2016","unstructured":"Chen KH, Chien Y, Wang KL et al (2016) Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy. Can J Cardiol 32:1221 e1221\u20131221 e1229. https:\/\/doi.org\/10.1016\/j.cjca.2015.10.033","journal-title":"Can J Cardiol"},{"key":"6420_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/8904_2014_371","volume":"22","author":"W Mauhin","year":"2015","unstructured":"Mauhin W, Lidove O, Masat E, Mingozzi F, Mariampillai K, Ziza JM, Benveniste O (2015) Innate and adaptive immune response in Fabry disease. JIMD Rep 22:1\u201310. https:\/\/doi.org\/10.1007\/8904_2014_371","journal-title":"JIMD Rep"},{"key":"6420_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/03009740903270631","volume":"39","author":"K Sacre","year":"2010","unstructured":"Sacre K, Lidove O, Giroux Leprieur B, Ouali N, Laganier J, Caillaud C, Papo T (2010) Bone and joint involvement in Fabry disease. Scand J Rheumatol 39:171\u2013174. https:\/\/doi.org\/10.3109\/03009740903270631","journal-title":"Scand J Rheumatol"},{"key":"6420_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","volume":"68","author":"DP Germain","year":"2005","unstructured":"Germain DP, Benistan K, Boutouyrie P, Mutschler C (2005) Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet 68:93\u201395. https:\/\/doi.org\/10.1111\/j.1399-0004.2005.00457.x","journal-title":"Clin Genet"},{"key":"6420_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/8904_2014_328","volume":"17","author":"A Talbot","year":"2014","unstructured":"Talbot A, Ghali JR, Nicholls K (2014) Antiepileptic medications increase osteoporosis risk in male Fabry patients: bone mineral density in an Australian cohort. JIMD Rep 17. Springer:29\u201336","journal-title":"JIMD Rep"},{"key":"6420_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jbspin.2015.11.001","volume":"83","author":"O Lidove","year":"2016","unstructured":"Lidove O, Zeller V, Chicheportiche V, Meyssonnier V, Sene T, Godot S, Ziza JM (2016) Musculoskeletal manifestations of Fabry disease: a retrospective study. Joint Bone Spine 83:421\u2013426. https:\/\/doi.org\/10.1016\/j.jbspin.2015.11.001","journal-title":"Joint Bone Spine"},{"key":"6420_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","volume":"73","author":"KB Sims","year":"2008","unstructured":"Sims KB, Pastores GM, Weinreb NJ et al (2008) Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 73:430\u2013440. https:\/\/doi.org\/10.1111\/j.1399-0004.2008.00978.x","journal-title":"Clin Genet"},{"key":"6420_CR9","doi-asserted-by":"publisher","first-page":"13333","DOI":"10.1074\/jbc.M210868200","volume":"278","author":"A Heiss","year":"2003","unstructured":"Heiss A, DuChesne A, Denecke B, Gr\u00f6tzinger J, Yamamoto K, Renn\u00e9 T, Jahnen-Dechent W (2003) Structural basis of calcification inhibition by \u03b12-HS glycoprotein\/fetuin-A: formation of colloidal calciprotein particles. J Biol Chem 278:13333\u201313341","journal-title":"J Biol Chem"},{"key":"6420_CR10","doi-asserted-by":"publisher","first-page":"14815","DOI":"10.1074\/jbc.M709938200","volume":"283","author":"A Heiss","year":"2008","unstructured":"Heiss A, Eckert T, Aretz A, Richtering W, van Dorp W, Schafer C, Jahnen-Dechent W (2008) Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem 283:14815\u201314825. https:\/\/doi.org\/10.1074\/jbc.M709938200","journal-title":"J Biol Chem"},{"key":"6420_CR11","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00223-017-0313-0","volume":"101","author":"MMX Cai","year":"2017","unstructured":"Cai MMX, Smith ER, Tan SJ, Hewitson TD, Holt SG (2017) The role of secondary calciprotein particles in the mineralisation paradox of chronic kidney disease. Calcif Tissue Int 101:570\u2013580. https:\/\/doi.org\/10.1007\/s00223-017-0313-0","journal-title":"Calcif Tissue Int"},{"key":"6420_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.molmed.2009.07.001","volume":"15","author":"V Persy","year":"2009","unstructured":"Persy V, D\u2019Haese P (2009) Vascular calcification and bone disease: the calcification paradox. Trends Mol Med 15:405\u2013416. https:\/\/doi.org\/10.1016\/j.molmed.2009.07.001","journal-title":"Trends Mol Med"},{"key":"6420_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00198-008-0648-5","volume":"20","author":"P Anagnostis","year":"2009","unstructured":"Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20:197\u2013207. https:\/\/doi.org\/10.1007\/s00198-008-0648-5","journal-title":"Osteoporos Int"},{"key":"6420_CR14","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1074\/jbc.M106366200","volume":"277","author":"PA Price","year":"2002","unstructured":"Price PA, Thomas GR, Pardini AW, Figueira WF, Caputo JM, Williamson MK (2002) Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem 277:3926\u20133934. https:\/\/doi.org\/10.1074\/jbc.M106366200","journal-title":"J Biol Chem"},{"key":"6420_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1359\/jbmr.2002.17.7.1171","volume":"17","author":"PA Price","year":"2002","unstructured":"Price PA, Caputo JM, Williamson MK (2002) Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. J Bone Miner Res 17:1171\u20131179. https:\/\/doi.org\/10.1359\/jbmr.2002.17.7.1171","journal-title":"J Bone Miner Res"},{"key":"6420_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/ndt\/gfz234","volume":"36","author":"I Bressendorff","year":"2021","unstructured":"Bressendorff I, Hansen D, Pasch A, Holt SG, Schou M, Brandi L, Smith ER (2021) The effect of increasing dialysate magnesium on calciprotein particles, inflammation and bone markers: post hoc analysis from a randomized controlled clinical trial. Nephrol Dial Transplant 36:713\u2013721. https:\/\/doi.org\/10.1093\/ndt\/gfz234","journal-title":"Nephrol Dial Transplant"},{"key":"6420_CR17","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/ndt\/gfr609","volume":"27","author":"ER Smith","year":"2012","unstructured":"Smith ER, Ford ML, Tomlinson LA, Rajkumar C, McMahon LP, Holt SG (2012) Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 27:1957\u20131966. https:\/\/doi.org\/10.1093\/ndt\/gfr609","journal-title":"Nephrol Dial Transplant"},{"key":"6420_CR18","doi-asserted-by":"publisher","first-page":"107436","DOI":"10.1016\/j.pharmthera.2019.107436","volume":"206","author":"JM Kim","year":"2020","unstructured":"Kim JM, Lee WS, Kim J (2020) Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis. Pharmacol Ther 206:107436. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107436","journal-title":"Pharmacol Ther"},{"key":"6420_CR19","doi-asserted-by":"publisher","first-page":"e10497","DOI":"10.1002\/jbm4.10497","volume":"5","author":"MK Tiong","year":"2021","unstructured":"Tiong MK, Smith ER, Toussaint ND, Al-Khayyat HF, Holt SG (2021) Reduction of calciprotein particles in adults receiving infliximab for chronic inflammatory disease. JBMR Plus 5:e10497. https:\/\/doi.org\/10.1002\/jbm4.10497","journal-title":"JBMR Plus"},{"key":"6420_CR20","doi-asserted-by":"publisher","first-page":"5282389","DOI":"10.1155\/2018\/5282389","volume":"2018","author":"K Akiyama","year":"2018","unstructured":"Akiyama K, Kimura T, Shiizaki K (2018) Biological and clinical effects of calciprotein particles on chronic kidney disease-mineral and bone disorder. Int J Endocrinol 2018:5282389. https:\/\/doi.org\/10.1155\/2018\/5282389","journal-title":"Int J Endocrinol"},{"key":"6420_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S (2017) Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab 122:19\u201327. https:\/\/doi.org\/10.1016\/j.ymgme.2017.09.004","journal-title":"Mol Genet Metab"},{"key":"6420_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/nep.12021","volume":"18","author":"ER Smith","year":"2013","unstructured":"Smith ER, Cai MM, McMahon LP, Pedagogos E, Toussaint ND, Brumby C, Holt SG (2013) Serum fetuin-A concentration and fetuin-A-containing calciprotein particles in patients with chronic inflammatory disease and renal failure. Nephrology (Carlton) 18:215\u2013221. https:\/\/doi.org\/10.1111\/nep.12021","journal-title":"Nephrology (Carlton)"},{"key":"6420_CR23","unstructured":"Whybra C, B\u00e4hner F, Baron K. (2006) Measurement of disease severity and progression in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis. Chapter 32. Available from:\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11612\/"},{"key":"6420_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/heartjnl-2014-306278","volume":"101","author":"AS Talbot","year":"2015","unstructured":"Talbot AS, Lewis NT, Nicholls KM (2015) Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease. Heart 101:287\u2013293. https:\/\/doi.org\/10.1136\/heartjnl-2014-306278","journal-title":"Heart"},{"key":"6420_CR25","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"RM Lang","year":"2005","unstructured":"Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440\u20131463. https:\/\/doi.org\/10.1016\/j.echo.2005.10.005","journal-title":"J Am Soc Echocardiogr"},{"key":"6420_CR26","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1681\/Asn.2012030240","volume":"23","author":"A Pasch","year":"2012","unstructured":"Pasch A, Farese S, Graber S, Wald J, Richtering W, Floege J, Jahnen-Dechent W (2012) Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 23:1744\u20131752. https:\/\/doi.org\/10.1681\/Asn.2012030240","journal-title":"J Am Soc Nephrol"},{"key":"6420_CR27","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s00198-013-2413-7","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, Adachi JD, Cooper C et al (2013) Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF. Osteoporos Int 24:2763\u20132764. https:\/\/doi.org\/10.1007\/s00198-013-2413-7","journal-title":"Osteoporos Int"},{"key":"6420_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137\u20131141. https:\/\/doi.org\/10.1002\/jbmr.5650090802","journal-title":"J Bone Miner Res"},{"key":"6420_CR29","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1038\/s41598-017-05474-y","volume":"7","author":"ER Smith","year":"2017","unstructured":"Smith ER, Hewitson TD, Cai MMX, Aghagolzadeh P, Bachtler M, Pasch A, Holt SG (2017) A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum. Sci Rep 7:5686. https:\/\/doi.org\/10.1038\/s41598-017-05474-y","journal-title":"Sci Rep"},{"key":"6420_CR30","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ekir.2020.06.014","volume":"5","author":"ER Smith","year":"2020","unstructured":"Smith ER, Pan FFM, Hewitson TD, Toussaint ND, Holt SG (2020) Effect of sevelamer on calciprotein particles in hemodialysis patients: the sevelamer versus calcium to reduce fetuin-A-containing calciprotein particles in dialysis (SCaRF) randomized controlled trial. Kidney Int Rep 5:1432\u20131447. https:\/\/doi.org\/10.1016\/j.ekir.2020.06.014","journal-title":"Kidney Int Rep"},{"key":"6420_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ymgme.2014.11.005","volume":"114","author":"M Fuller","year":"2015","unstructured":"Fuller M, Mellett N, Hein LK, Brooks DA, Meikle PJ (2015) Absence of alpha-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts. Mol Genet Metab 114:268\u2013273. https:\/\/doi.org\/10.1016\/j.ymgme.2014.11.005","journal-title":"Mol Genet Metab"},{"key":"6420_CR32","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.kint.2019.10.019","volume":"97","author":"KI Akiyama","year":"2020","unstructured":"Akiyama KI, Miura Y, Hayashi H et al (2020) Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts. Kidney Int 97:702\u2013712. https:\/\/doi.org\/10.1016\/j.kint.2019.10.019","journal-title":"Kidney Int"},{"key":"6420_CR33","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.kint.2019.12.018","volume":"97","author":"W Jahnen-Dechent","year":"2020","unstructured":"Jahnen-Dechent W, Smith ER (2020) Nature\u2019s remedy to phosphate woes: calciprotein particles regulate systemic mineral metabolism. Kidney Int 97:648\u2013651. https:\/\/doi.org\/10.1016\/j.kint.2019.12.018","journal-title":"Kidney Int"},{"key":"6420_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000489672","volume":"47","author":"SM Ott","year":"2018","unstructured":"Ott SM (2018) Cortical or trabecular bone: what\u2019s the difference? Am J Nephrol 47:373\u2013375. https:\/\/doi.org\/10.1159\/000489672","journal-title":"Am J Nephrol"},{"key":"6420_CR35","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.ymgmr.2019.100529","volume":"21","author":"M Beck","year":"2019","unstructured":"Beck M, Cox TM (2019) Comment: why are females with Fabry disease affected? Mol Genet Metab Rep 21:100529. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100529","journal-title":"Mol Genet Metab Rep"},{"key":"6420_CR36","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","volume":"107","author":"M Pieroni","year":"2003","unstructured":"Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A (2003) Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107:1978\u20131984. https:\/\/doi.org\/10.1161\/01.CIR.0000061952.27445.A0","journal-title":"Circulation"},{"key":"6420_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331\u2013341. https:\/\/doi.org\/10.1111\/joim.12077","journal-title":"J Intern Med"},{"key":"6420_CR38","doi-asserted-by":"publisher","first-page":"e4810","DOI":"10.1097\/MD.0000000000004810","volume":"95","author":"F Meng","year":"2016","unstructured":"Meng F, Wang W, Ma J, Lin B (2016) Parathyroid hormone and risk of heart failure in the general population: a meta-analysis of prospective studies. Medicine (Baltimore) 95:e4810. https:\/\/doi.org\/10.1097\/MD.0000000000004810","journal-title":"Medicine (Baltimore)"},{"key":"6420_CR39","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/gim.0b013e31815cb197","volume":"9","author":"H Mersebach","year":"2007","unstructured":"Mersebach H, Johansson JO, Rasmussen AK, Bengtsson BA, Rosenberg K, Hasholt L, Sorensen SA, Sorensen SS, Feldt-Rasmussen U (2007) Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med 9:812\u2013818. https:\/\/doi.org\/10.1097\/gim.0b013e31815cb197","journal-title":"Genet Med"},{"key":"6420_CR40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.atherosclerosis.2016.05.044","volume":"251","author":"P Aghagolzadeh","year":"2016","unstructured":"Aghagolzadeh P, Bachtler M, Bijarnia R, Jackson C, Smith ER, Odermatt A, Radpour R, Pasch A (2016) Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-\u03b1. Atherosclerosis 251:404\u2013414","journal-title":"Atherosclerosis"},{"key":"6420_CR41","doi-asserted-by":"publisher","first-page":"e026876","DOI":"10.1136\/bmjopen-2018-026876","volume":"10","author":"AL Barker","year":"2020","unstructured":"Barker AL, Soh SE, Sanders KM et al (2020) Aspirin and fracture risk: a systematic review and exploratory meta-analysis of observational studies. BMJ Open 10:e026876. https:\/\/doi.org\/10.1136\/bmjopen-2018-026876","journal-title":"BMJ Open"},{"key":"6420_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.afos.2017.02.001","volume":"3","author":"YS Kim","year":"2017","unstructured":"Kim YS, Han JJ, Lee J, Choi HS, Kim JH, Lee T (2017) The correlation between bone mineral density\/trabecular bone score and body mass index, height, and weight. Osteoporos Sarcopenia 3:98\u2013103. https:\/\/doi.org\/10.1016\/j.afos.2017.02.001","journal-title":"Osteoporos Sarcopenia"},{"key":"6420_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","volume":"61","author":"R Thadhani","year":"2002","unstructured":"Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249\u2013255. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00097.x","journal-title":"Kidney Int"},{"key":"6420_CR44","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1007\/BF01540061","volume":"34","author":"G Nelis","year":"1989","unstructured":"Nelis G, Jacobs G (1989) Anorexia, weight loss, and diarrhea as presenting symptoms of angiokeratoma corporis diffusum (Fabry-Anderson\u2019s disease). Dig Dis Sci 34:1798\u20131800","journal-title":"Dig Dis Sci"},{"key":"6420_CR45","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/1756283X16642936","volume":"9","author":"C Zar-Kessler","year":"2016","unstructured":"Zar-Kessler C, Karaa A, Sims KB, Clarke V, Kuo B (2016) Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis. Ther Adv Gastroenterol 9:626\u2013634. https:\/\/doi.org\/10.1177\/1756283X16642936","journal-title":"Ther Adv Gastroenterol"},{"key":"6420_CR46","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/nep.12994","volume":"23","author":"H Yamada","year":"2018","unstructured":"Yamada H, Kuro OM, Ishikawa SE, Funazaki S, Kusaka I, Kakei M, Hara K (2018) Daily variability in serum levels of calciprotein particles and their association with mineral metabolism parameters: a cross-sectional pilot study. Nephrology (Carlton) 23:226\u2013230. https:\/\/doi.org\/10.1111\/nep.12994","journal-title":"Nephrology (Carlton)"},{"key":"6420_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","volume":"126","author":"F Weidemann","year":"2019","unstructured":"Weidemann F, Beer M, Kralewski M, Siwy J, Kampmann C (2019) Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study. Mol Genet Metab 126:169\u2013182. https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.005","journal-title":"Mol Genet Metab"},{"key":"6420_CR48","doi-asserted-by":"publisher","first-page":"e007124","DOI":"10.1161\/jaha.117.007124","volume":"7","author":"P Aguiar","year":"2018","unstructured":"Aguiar P, Azevedo O, Pinto R, Marino J, Cardoso C, Sousa N, Cunha D, Hughes D, Ducla Soares JL (2018) Biomarkers of myocardial Fibrosis: revealing the natural history of fibrogenesis in Fabry disease cardiomyopathy. J Am Heart Assoc 7:e007124. https:\/\/doi.org\/10.1161\/jaha.117.007124","journal-title":"J Am Heart Assoc"},{"key":"6420_CR49","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/0003319720981521","volume":"72","author":"AC Vujkovac","year":"2021","unstructured":"Vujkovac AC, Vujkovac B, Novakovi\u0107 S, \u0160tevanec M, \u0160abovi\u010d M (2021) Characteristics of vascular phenotype in Fabry patients. Angiology 72:426\u2013433. https:\/\/doi.org\/10.1177\/0003319720981521","journal-title":"Angiology"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06420-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06420-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06420-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T17:10:43Z","timestamp":1663866643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06420-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6420"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06420-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"24 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the <i>Melbourne Health Human Research Ethics Committee (#2012.141 & #2001.144).<\/i>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors read and approved the final manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ERS owns stock in Calciscon AG, which commercializes the T<sub>50<\/sub> test and reports research funding from Amgen and Sanofi, outside the submitted work. SB reports no relevant conflicts of interest. KMN reports no relevant conflicts of interest. TDH reports no relevant conflicts of interest. AST reports no relevant conflicts of interest. SGH reports no relevant conflicts of interest. IR reports no relevant conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}